Is Symbiox Investme overvalued or undervalued?

As of 13 November 2025, the valuation grade for Symbiox Investme has moved from attractive to risky. This indicates a significant deterioration in its valuation outlook, leading to the conclusion that the company is overvalued. The PE ratio stands at an alarming -938.62, while the EV to EBIT and EV to EBITDA ratios are both at 4.74, suggesting inefficiencies in generating earnings relative to its enterprise value.
When compared to peers, Symbiox Investme's ratios starkly contrast with those of Bajaj Finance, which has a PE ratio of 34.18, and Life Insurance, which boasts a PE of 11.18. The negative return on equity (ROE) of -0.03% further underscores the company's struggles, especially when juxtaposed with the more stable financial metrics of its competitors. Despite a recent uptick in stock performance relative to the Sensex over the past week and month, the broader year-to-date and one-year returns of -44.65% and -16.67%, respectively, highlight persistent underperformance in the long term.